Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free FAB Stock Alerts

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 9.05 -2.30 (-20.26%)
As of 11:58 AM Eastern
Compare

FAB vs. REDX, ETX, HVO, COIL, and HEMO

Should you buy Fusion Antibodies stock or one of its competitors? Fusion Antibodies's main competitors and comparable companies include Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), Roquefort Therapeutics (COIL), and Hemogenyx Pharmaceuticals (HEMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to Redx Pharma?

Redx Pharma (LON:REDX) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Redx Pharma has a beta of -0.53, suggesting that its share price is 153% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, suggesting that its share price is 24% more volatile than the broader market.

Fusion Antibodies has lower revenue, but higher earnings than Redx Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A
Fusion Antibodies£1.60M7.10-£4.10M-£1.50N/A

In the previous week, Fusion Antibodies had 3 more articles in the media than Redx Pharma. MarketBeat recorded 3 mentions for Fusion Antibodies and 0 mentions for Redx Pharma. Fusion Antibodies' average media sentiment score of 1.68 beat Redx Pharma's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company Overall Sentiment
Redx Pharma Neutral
Fusion Antibodies Very Positive

72.7% of Redx Pharma shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 18.4% of Redx Pharma shares are owned by insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Redx Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Redx Pharma's return on equity of -180.80% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Redx PharmaN/A -180.80% -43.95%
Fusion Antibodies -91.92%-210.32%-63.78%

Summary

Redx Pharma beats Fusion Antibodies on 7 of the 12 factors compared between the two stocks.

How does Fusion Antibodies compare to e-therapeutics?

Fusion Antibodies (LON:FAB) and e-therapeutics (LON:ETX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by company insiders. Comparatively, 59.4% of e-therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
e-therapeutics N/A -38.75%-29.10%

In the previous week, Fusion Antibodies had 3 more articles in the media than e-therapeutics. MarketBeat recorded 3 mentions for Fusion Antibodies and 0 mentions for e-therapeutics. Fusion Antibodies' average media sentiment score of 1.68 beat e-therapeutics' score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.

Company Overall Sentiment
Fusion Antibodies Very Positive
e-therapeutics Neutral

Fusion Antibodies has a beta of 1.244, indicating that its share price is 24% more volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M7.10-£4.10M-£1.50N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

Summary

Fusion Antibodies and e-therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Fusion Antibodies compare to hVIVO?

hVIVO (LON:HVO) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Fusion Antibodies -91.92%-210.32%-63.78%

hVIVO has a beta of 1.694, meaning that its stock price is 69% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, meaning that its stock price is 24% more volatile than the broader market.

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M0.94£17.84M-£0.87N/A
Fusion Antibodies£1.60M7.10-£4.10M-£1.50N/A

In the previous week, Fusion Antibodies had 3 more articles in the media than hVIVO. MarketBeat recorded 3 mentions for Fusion Antibodies and 0 mentions for hVIVO. Fusion Antibodies' average media sentiment score of 1.68 beat hVIVO's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company Overall Sentiment
hVIVO Neutral
Fusion Antibodies Very Positive

12.7% of hVIVO shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

hVIVO presently has a consensus target price of GBX 15, indicating a potential upside of 134.38%. Given hVIVO's stronger consensus rating and higher possible upside, analysts plainly believe hVIVO is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

hVIVO beats Fusion Antibodies on 11 of the 16 factors compared between the two stocks.

How does Fusion Antibodies compare to Roquefort Therapeutics?

Fusion Antibodies (LON:FAB) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Fusion Antibodies has a net margin of -91.92% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by company insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Fusion Antibodies has a beta of 1.244, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

In the previous week, Fusion Antibodies had 3 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 3 mentions for Fusion Antibodies and 0 mentions for Roquefort Therapeutics. Fusion Antibodies' average media sentiment score of 1.68 beat Roquefort Therapeutics' score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.

Company Overall Sentiment
Fusion Antibodies Very Positive
Roquefort Therapeutics Neutral

Roquefort Therapeutics has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M7.10-£4.10M-£1.50N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Fusion Antibodies beats Roquefort Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Fusion Antibodies compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Fusion Antibodies (LON:FAB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

Hemogenyx Pharmaceuticals has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Fusion Antibodies£1.60M7.10-£4.10M-£1.50N/A

In the previous week, Fusion Antibodies had 3 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 3 mentions for Fusion Antibodies and 0 mentions for Hemogenyx Pharmaceuticals. Fusion Antibodies' average media sentiment score of 1.68 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the news media.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Fusion Antibodies Very Positive

Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its share price is 49% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.244, meaning that its share price is 24% more volatile than the broader market.

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Fusion Antibodies -91.92%-210.32%-63.78%

Summary

Hemogenyx Pharmaceuticals and Fusion Antibodies tied by winning 6 of the 12 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

Export
MetricFusion AntibodiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£11.33M£3.88B£7.20B£2.87B
Dividend YieldN/A3.66%2.57%6.25%
P/E Ratio-6.0314.40273.84367.03
Price / Sales7.101,432.88638.3289,972.82
Price / Cash9.0243.6428.4227.89
Price / Book2.5815.2610.436.30
Net Income-£4.10M-£22.78M£3.49B£5.89B
7 Day Performance-24.58%-2.03%-2.11%-1.13%
1 Month Performance-10.88%2.10%0.64%-0.61%
1 Year Performance-43.40%42.58%24.61%19.59%

Fusion Antibodies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 9.05
-20.3%		N/A-29.0%£11.33M£1.60MN/A48
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HVO
hVIVO
N/AGBX 7.20
+4.3%		GBX 15
+108.3%		-32.0%£49.57M£46.77MN/AN/A
COIL
Roquefort Therapeutics
N/AGBX 8.13
+0.3%		N/A-58.5%£34.68MN/AN/A9

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FAB) was last updated on 9/14/2026 by MarketBeat.com Staff.
From Our Partners
By election night, it's already too late
The November 3rd, 2026 midterms could flip control of Congress, putting taxes, spending, and retirement rules ...
American Alternative | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Jon Najarian's #1 Energy Trade for 2026
Jon Najarian says he's never been more excited about an energy opportunity. SpaceX just went public at over $2...
Banyan Hill Publishing | Sponsoredtc pixel
CFA: Decentralized AI is the Next Wave
Don't buy Nvidia... Not when the AI companies that will define the next decade are selling for pennies. You wo...
Decentralized Masters | Sponsoredtc pixel
Gold majors have a big problem
Newmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...
Golden Portfolio | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel